CDK2 and cancer: Reduction in the activity of Cdk2 by antiprogestins is relevant from a therapeutic standpoint because Cdk2 is often upregulated in ovarian cancer cells (Sui et al. 2001) and has been shown to be a valuable targetable molecule in ovarian (Etemadmoghadam et al. 2013) and breast (Achille et al. 2012), as well as other human cancer cells (Molenaar et al. 2009, Long et al. 2010).